Evaluation of nucleoside reverse transcriptase inhibitor dosing during continuous veno-venous hemofiltration

被引:2
作者
McLaughlin, Milena M. [1 ,2 ]
Masic, Inela [1 ]
Gerzenshtein, Lana [2 ]
机构
[1] Midwestern Univ, Chicago Coll Pharm, Dept Pharm Practice, 555 31st St, Downers Grove, IL 60515 USA
[2] Northwestern Mem Hosp, 251 E Huron St, Chicago, IL 60611 USA
关键词
Continuous veno-vous hemofiltration; HIV; Nucleoside reverse transcriptase inhibitor; Pharmacokinetics; NRTIs; ANTIRETROVIRAL THERAPY;
D O I
10.1007/s11096-016-0401-7
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background Unpredictable drug concentrations may lead to suboptimal exposure to nucleoside reverse transcriptase inhibitors (NRTIs) due to inadequate doses administered during continuous veno-venous hemofiltration (CVVH), which in turn may lead to decreased antiretroviral efficacy and possibly further HIV disease progression. Objective To compare administered doses of NRTIs to calculated doses of NRTIs to evaluate if patients were expected to have a favorable pharmacokinetic exposure profile while receiving CVVH. Methods The NRTI dose was compared to a table of recommendations based on a mathematical formula that estimates the amount of drug expected to be removed during CVVH. Results Twelve patients were on 27 NRTIs. Eleven (41%) NRTI doses were expected to provide a favorable pharmacokinetic profile based on pharmacokinetic mathematical calculations. Conclusion The majority of NRTIs were potentially not optimally dosed based on proposed pharmacokinetic calculations.
引用
收藏
页码:37 / 40
页数:4
相关论文
共 10 条
[1]   Renal Toxicity Associated With Antiretroviral Therapy [J].
Calza, Leonardo .
HIV CLINICAL TRIALS, 2012, 13 (04) :189-211
[2]   Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice [J].
Fabbiani, Massimiliano ;
Di Giambenedetto, Simona ;
Bracciale, Laura ;
Bacarelli, Alessandra ;
Ragazzoni, Enzo ;
Cauda, Roberto ;
Navarra, Pierluigi ;
De Luca, Andrea .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 64 (01) :109-117
[3]   Concentration-controlled compared with conventional antiretroviral therapy for HIV infection [J].
Fletcher, CV ;
Anderson, PL ;
Kakuda, TN ;
Schacker, TW ;
Henry, K ;
Gross, CR ;
Brundage, RC .
AIDS, 2002, 16 (04) :551-560
[4]   Current concepts: Continuous hemofiltration in the treatment of acute renal failure [J].
Forni, LG ;
Hilton, PJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (18) :1303-1309
[5]  
Golper TA, 1998, KIDNEY INT, V53, pS165
[6]   Guidelines for the management of chronic kidney disease in HIV-infected patients: Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America [J].
Gupta, SK ;
Eustace, JA ;
Winston, JA ;
Boydstun, II ;
Ahuja, TS ;
Rodriguez, RA ;
Tashima, KT ;
Roland, M ;
Franceschini, N ;
Palella, FJ ;
Lennox, JL ;
Klotman, PE ;
Nachman, SA ;
Hall, SD ;
Szczech, LA .
CLINICAL INFECTIOUS DISEASES, 2005, 40 (11) :1559-1585
[7]   Antiretroviral therapy - Pharmacokinetic considerations in patients with renal or hepatic impairment [J].
McCabe, Sarah M. ;
Ma, Qing ;
Slish, Judianne C. ;
Catanzaro, Linda M. ;
Sheth, Neha ;
DiCenzo, Robert ;
Morse, Gene D. .
CLINICAL PHARMACOKINETICS, 2008, 47 (03) :153-172
[8]   Dosing Nucleoside Reverse Transcriptase Inhibitors in Adults Receiving Continuous Veno-Venous Hemofiltration [J].
McLaughlin, Milena M. ;
Ammar, Abeer T. ;
Gerzenshtein, Lana ;
Scarsi, Kimberly K. .
CLINICAL DRUG INVESTIGATION, 2015, 35 (04) :275-280
[9]  
Prakash J, 2015, Indian J Nephrol, V25, P86, DOI 10.4103/0971-4065.138696
[10]  
Uchino S, 2007, INTENS CARE MED, V33, P1563, DOI 10.1007/s00134-007-0754-4